Yes I could well believe that there was a much better SSRI out there someplace waiting to be discovered. I just think it is unlikely that any company is going to want to spend big bucks trying to find it given the current environment.
Of course if there is some sort of scientific breakthrough enhancing our currently limited understanding of how this class works, that could change things. So my pessimism here is short- and mid-term, not necessarily long-term.
Agree, SSRIs and SNRIs still leave a lot of room for improvement, both in terms of efficacy (remission rates) and tolerability, not to mention faster time of onset which by itself could be a differentiating advantage.
Market Data 
Markets 
AI
